Cingulate Inc. Common Stock (CING) is a publicly traded Healthcare sector company. As of May 21, 2026, CING trades at $4.64 with a market cap of $59.48M and a P/E ratio of -1.07. CING moved +5.92% today. Year to date, CING is -2.53%; over the trailing twelve months it is +27.90%. Its 52-week range spans $3.02 to $11.89. Analyst consensus is strong buy with an average price target of $25.67. Rallies surfaces CING's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Cingulate Secures $12M PIPE, NDA Accepted with May 31 PDUFA Date: Cingulate’s NDA for CTx-1301 was accepted under the FDA’s 505(b)(2) pathway with a PDUFA target action date of May 31, 2026, based on Phase 3 trials showing rapid-onset and sustained ADHD control. The company secured $12 million in PIPE financing, bolstered its patent estate with a U.S. Notice of Allowance and a European patent extending protection to May 2042.
| Metric | Value |
|---|---|
| Price | $4.64 |
| Market Cap | $59.48M |
| P/E Ratio | -1.07 |
| EPS | $-4.23 |
| Dividend Yield | 0.00% |
| 52-Week High | $11.89 |
| 52-Week Low | $3.02 |
| Volume | 2.69K |
| Avg Volume | 0 |
| Revenue (TTM) | $-1.79M |
| Net Income | $-27.91M |
| Gross Margin | 0.00% |
3 analysts cover CING: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $25.67.